Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

SUZHOU, China, Dec. 10, 2019 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of o... Biopharmaceuticals, Oncology Innovent Biologics, IASO Biotherapeutics, BCMA CAR-T, Cell Therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news